Articles related to OSTEOPOROSIS

Clinical trials reveal that osteoporosis screening is associated with five to six fewer fractures per 1,000 participants compared to usual care, providing concrete evidence for screening’s clinical value.

Convincing bone loss would be bone loss at more than 1 site or over more than 1 interval, or bone loss associated with elevated markers of bone turnover such as cross-linked C-telopeptide of type-1 collagen (CTx) greater than 300 pg/mL.

The study found that psychosocial factors had the most significant impact on postmenopausal women’s quality of life, with 26.6% of participants reporting accomplishing less than usual.

Addressing the Underrecognized Issue of Male Osteoporosis: Evidence-based Strategies for Improved Detection and Management As the elderly population increases, osteoporosis in men, a condition often underdiagnosed and overlooked, is gaining significant prominence in public health. This self-learning activity enables healthcare professionals to gain critical insight into this issue and empower them with the latest evidence-based preventive and therapeutic strategies.

Internal medicine physicians play a crucial role in addressing osteoporosis challenges. Many at-risk patients are not screened or educated about fracture prevention, and a significant number of individuals with high fracture risk remain undiagnosed and untreated. Efforts should focus on recognizing fractures as diagnostic indicators, expanding screening, and implementing effective treatments. The recent clinical guideline emphasizes bisphosphonates as first-line therapy, denosumab as second-line, and injectable medications for high-risk cases. Primary care physicians should take an active role in screening, diagnosing, and treating osteoporosis to prevent future fractures, even without immediate subspecialist care. Risk assessment tools, healthy lifestyles, and consideration of benefits, harms, patient values, and costs in medication selection are important. Empowering primary care doctors is vital in bridging the treatment gap and preventing fractures.

Clinical trials of abaloparatide, a human parathyroid hormone related peptide analog, showed significantly increased bone mineral density at 12 months in the lumbar spine and femoral neck in men with osteoporosis.